BR0112661A - Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica - Google Patents

Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica

Info

Publication number
BR0112661A
BR0112661A BR0112661-0A BR0112661A BR0112661A BR 0112661 A BR0112661 A BR 0112661A BR 0112661 A BR0112661 A BR 0112661A BR 0112661 A BR0112661 A BR 0112661A
Authority
BR
Brazil
Prior art keywords
antagonist
receptor
pharmaceutical formulation
new combination
agonist
Prior art date
Application number
BR0112661-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Sukhwinder Jossan
Bjoern Nilsson
Kjell Sakariassen
Jan Svartengren
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of BR0112661A publication Critical patent/BR0112661A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
BR0112661-0A 2000-07-21 2001-07-19 Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica BR0112661A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BR0112661A true BR0112661A (pt) 2003-06-24

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112661-0A BR0112661A (pt) 2000-07-21 2001-07-19 Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica

Country Status (18)

Country Link
EP (1) EP1301476A1 (enExample)
JP (1) JP2004504376A (enExample)
KR (1) KR100845450B1 (enExample)
CN (1) CN1221254C (enExample)
AU (2) AU2001282734B2 (enExample)
BR (1) BR0112661A (enExample)
CA (1) CA2411192A1 (enExample)
EA (1) EA006604B1 (enExample)
HU (1) HUP0301346A3 (enExample)
IL (1) IL154057A0 (enExample)
MX (1) MXPA03000548A (enExample)
NO (1) NO20030304L (enExample)
NZ (1) NZ523216A (enExample)
PL (1) PL360309A1 (enExample)
SE (1) SE0002754D0 (enExample)
WO (1) WO2002008178A1 (enExample)
YU (1) YU2603A (enExample)
ZA (1) ZA200210234B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036562A2 (en) * 2000-11-02 2002-05-10 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
JP2005501019A (ja) * 2001-06-15 2005-01-13 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
RS20060035A (sr) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Derivati diaril i arilheteroaril uree kao modulatori receptora 5-ht2a serotonina korisni u profilaksi i lečenju poremećaja u vezi sa njima
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
EP2020230B1 (en) * 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
HRP20140589T1 (hr) 2009-06-15 2014-08-01 Takeda Pharmaceutical Company Limited Derivati pirazinooksazepina
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
MXPA03000548A (es) 2004-04-05
AU2001282734B2 (en) 2006-10-12
CN1443162A (zh) 2003-09-17
KR20030036599A (ko) 2003-05-09
SE0002754D0 (sv) 2000-07-21
WO2002008178A1 (en) 2002-01-31
EA200300183A1 (ru) 2003-08-28
KR100845450B1 (ko) 2008-07-10
CN1221254C (zh) 2005-10-05
EP1301476A1 (en) 2003-04-16
HUP0301346A2 (hu) 2003-08-28
CA2411192A1 (en) 2002-01-31
IL154057A0 (en) 2003-07-31
AU8273401A (en) 2002-02-05
ZA200210234B (en) 2004-03-18
PL360309A1 (en) 2004-09-06
NZ523216A (en) 2005-05-27
EA006604B1 (ru) 2006-02-24
HUP0301346A3 (en) 2005-05-30
NO20030304L (no) 2003-03-12
YU2603A (sh) 2006-05-25
HK1057536A1 (en) 2004-04-08
NO20030304D0 (no) 2003-01-20
JP2004504376A (ja) 2004-02-12

Similar Documents

Publication Publication Date Title
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
KR101140510B1 (ko) 우울증 치료용 로티고틴의 용도
CN101534809B (zh) 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0110420A (pt) Agonistas muscarìnicos
BR0111207A (pt) Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
HUT77966A (hu) II.Típusú ösztrogénreceptor antagonista hatású flavanolignánokat tartalmazó antiproliferatív hatású gyógyszerkészítmények és azok előállítása
EP0871488A4 (en) ANAL-SAFE SYNERGY THROUGH SIMULTANEOUS ADMINISTRATION OF SUBANAL-SIDED CANES FROM A MU OPIOID ANAGONIST AND A KAPPA - 2 OPIOID ANAGONIST
BR9810773A (pt) Uso de um ingrediente anestésico local de ação prolongada, composição farmacêutica, uso de um anestésico local, e, kit
BR9914901A (pt) Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
BR0200246A (pt) Tratamento de combinação para a depressão
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
BR9915951A (pt) Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
UA87980C2 (ru) Композиция для улучшения познания и памяти
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOVITRUM AB (PUBL) (SE)

Free format text: ALTERADO DE: BIOVITRUM AB

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.